India's Sanofi-origin consumer healthcare (FMCH) firm behind Allegra, Combiflam, Avil and DePURA.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY24 | FY25 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 2 | 23 | — | 23 | 23 |
| Reserves | 206 | 250 | — | 234 | 361 |
| Borrowings | 0 | 20 | — | 28 | 25 |
| Other Liabilities | 138 | 138 | — | 137 | 138 |
| Total Liabilities | 345 | 431 | — | 422 | 547 |
| AssetsFixed Assets | 5 | 29 | — | 42 | 36 |
| CWIP | 3 | 1 | — | 0 | 0 |
| Investments | 0 | 0 | — | 0 | 0 |
| Other Assets | 338 | 402 | — | 380 | 511 |
| Total Assets | 345 | 431 | — | 422 | 547 |
| Line item | FY24 | FY25 | FY25 | FY26 |
|---|---|---|---|---|
| ActivitiesCash from Operating | 0 | 439 | — | 175 |
| Cash from Investing | 0 | 2 | — | 8 |
| Cash from Financing | 2 | -116 | — | -134 |
| SummaryCapital Expenditure | — | — | — | — |
| Free Cash Flow | -4 | 429 | — | 167 |
| FCF Margin | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (52.0×) and current (42.3×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 48.2% growth and a 42× exit, ₹4567 only delivers your return if you pay ₹16,438. The price is currently baking in 18% growth.
EPS grows 48.2%/yr for 5 years, then fades to 6% over 2, exits at 42×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 48.2% | 160.19 |
| FY28 | 48.2% | 237.40 |
| FY29 | 48.2% | 351.83 |
| FY30 | 48.2% | 521.41 |
| FY31 | 48.2% | 772.73 |
| FY32 | 27.1% ·fade | 982.14 |
| FY33 | 6.0% ·fade | 1041.07 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.